top of page

All4Cure Named 2025 Prix Galien USA Nominee for Best Digital Health Solution

  • Writer: Leena Chhun
    Leena Chhun
  • Aug 13
  • 1 min read
ree

We are proud to announce that All4Cure has been selected as a 2025 Prix Galien USA Nominee for Best Digital Health Solution.

The Prix Galien is one of the most prestigious honors in the life sciences, celebrating groundbreaking achievements that improve and extend lives around the world. This year’s nomination recognizes All4Cure’s innovative digital health platform, which connects patients, providers, and researchers to enable precision care and collaborative learning—driving better outcomes for people living with cancer.


“Being recognized among such an outstanding group of innovators is a testament to the dedication, expertise, and passion of our entire team,” said Kati O'Brien VP, Operations of All4Cure. “This nomination validates our belief that when patients, clinicians, and researchers work together, we can accelerate progress and transform cancer care.”


Winners will be announced at the Prix Galien USA Awards Ceremony on October 30, 2025, at the American Museum of Natural History in New York City.


This achievement would not be possible without the support of our incredible team, the trust of our patient and provider community, and the collaboration of our research partners. We share this honor with all of you.


About All4Cure

All4Cure is a best-in-class digital health platform that connects patients, medical providers, and researchers to enable precision care and collaborative learning. Our mission is to harness collective intelligence to save lives and transform patient outcomes.


Learn more about the Prix Galien USA Awards: https://www.galienfoundation.org/prix-galien-usa


Recent Posts

See All
Oncology Times - Melflufen

In a recent article published in Oncology Times, Dr. Tony Blau was interviewed along with Dr. Paul Richardson, Dr. Yvonne Efebera, and Dr. Heinz Ludwig about Melflufen (Melphalan Flufenamide). The FDA

 
 
bottom of page